Testosterone replacement therapy is one of the most over-marketed and under-monitored interventions in men's health. The advertising suggests that any man past forty who is tired, distracted, or thicker around the waist than he used to be is a candidate. The clinical reality is narrower, more useful, and less flattering to the chain-clinic model.
TRT is a real medical therapy with real upside for the right patient and real downside for the wrong one. The American Urological Association and the Endocrine Society both publish guidelines that say roughly the same thing: low testosterone should be confirmed biochemically, attributable to symptoms, and treated with appropriate monitoring. Here is what that looks like in practice.
Who actually benefits from TRT
TRT is appropriate for men with both biochemical low testosterone (confirmed on at least two early-morning total testosterone measurements) and clinical symptoms consistent with hypogonadism. The AUA threshold is a total testosterone below 300 ng/dL. Symptoms that matter include reduced libido, erectile dysfunction not better explained by vascular or psychogenic causes, persistent fatigue, depressed mood, decreased lean mass, and decreased bone density.
Men with both pieces — low number and matching symptoms — tend to respond well. Men with the number but no symptoms, or symptoms but normal levels, are a different conversation. Treating the lab value in isolation is the most common mistake we see when we take over care from a chain clinic.
What a real workup looks like
A proper baseline is not one number. Before starting therapy, we want total testosterone (drawn between 7 and 10 a.m., fasted, on at least two separate days), free testosterone, SHBG, estradiol (sensitive assay), LH, FSH, hematocrit, a comprehensive metabolic panel, a lipid panel, hs-CRP, HbA1c, and a PSA in men over 40 or with risk factors.
The LH and FSH matter. They tell us whether low testosterone is primary (testicular) or secondary (pituitary or hypothalamic). A young man with secondary hypogonadism and unexplained low LH deserves a workup for pituitary causes before he gets a prescription. A man with primary hypogonadism and elevated LH has a different conversation about fertility preservation.
We also screen for sleep apnea, depression, opioid use, recent significant weight gain, and anabolic steroid history. Each of these is a common driver of suppressed testosterone that responds better to addressing the cause than to TRT.
What to expect on the timeline
TRT is not a same-week intervention. Libido and energy often improve in three to six weeks. Mood follows over six to twelve weeks. Body composition changes (lean mass up, fat mass down) generally show up between three and six months. Bone density changes take a year or more.
Patients who expect dramatic next-week results are usually disappointed. Patients who give the protocol six months — with proper labs at six weeks, three months, and six months — usually have a clear picture of whether it is working.
Monitoring is the part chain clinics skip
TRT requires ongoing surveillance. The Endocrine Society guidelines outline what should be checked and when. Our standard monitoring includes:
- Total testosterone and free testosterone at six weeks, three months, six months, then every six to twelve months.
- Hematocrit at baseline, three months, six months, then annually — erythrocytosis is the most common dose-limiting side effect.
- Estradiol if symptoms suggest excess conversion (breast tenderness, water retention, mood changes).
- PSA at baseline, six months, twelve months, then annually — TRT does not cause prostate cancer, but it can accelerate an undiagnosed one.
- Lipid panel and HbA1c annually.
- Symptom review and dose adjustment at every visit.
When NOT to start
There are absolute and relative contraindications that every prescribing clinician should walk a patient through before the first injection:
- Active, untreated prostate cancer.
- Active, untreated breast cancer in men.
- Hematocrit above 54% at baseline (must be corrected first).
- Untreated severe obstructive sleep apnea.
- Severe untreated lower urinary tract symptoms or BPH.
- Desire for fertility in the near term — TRT suppresses spermatogenesis and is not a fertility-friendly therapy without adjuncts.
- Recent cardiovascular event within six months (relative — requires cardiology coordination).
What the chain clinics get wrong
The most common pattern we see is a single random testosterone draw, a same-week prescription, and a flat monthly fee that includes the medication but no real follow-up. Hematocrit is checked rarely or not at all. PSA is skipped. Estradiol is ignored until breast tenderness or mood changes force the conversation. Dose adjustments are based on how the patient feels rather than how the labs look.
This pattern works fine for the patients who happen to land on the right dose by accident. For the rest, it generates avoidable complications and a slow drift away from optimal — until something noticeable goes wrong.
How we do it
A proper TRT workup starts with an unhurried first visit, complete baseline labs, and an honest conversation about whether the symptoms and the numbers match. If they do, we discuss delivery route, dosing, monitoring schedule, and the off-ramp before the first dose is prescribed. Your provider still picks up the phone. Membership billing terms are explained before enrollment, without pressure to add ancillary medications you do not need.
TRT, done correctly, is one of the most rewarding therapies in men's health. Done casually, it is a slow accumulation of avoidable problems. The difference is the workup, the monitoring, and the clinician on the other side of the table.